Recently, Life Sciences Review conducted comprehensive research and evaluation of innovative companies in the field of life sciences in the Asia-Pacific region, and selected the "Top 10 Clinical Stage Biopharmaceutical Companies in APAC 2023", Zhuhai Trinomab Pharmaceutical Co., Ltd. was honored on the list.

Trinomab has been honored on the "Top 10 Clinical Stage Biopharmaceutical Companies in APAC 2023"
(Image source: Life Sciences Review)

Life Sciences Review is a platform that converges the worlds of life sciences, biotechnology, pharmaceuticals, and healthcare. It focuses on the life science and technology companies in the Asia-Pacific region, and selected the "Top 10 Clinical Stage Biopharmaceutical Companies in APAC 2023" based on factors such as innovation, clinical achievements, and regional influence. This award aims to recognize innovative biopharmaceutical companies that have made significant achievements in clinical research and promote the development of the industry.
 
Trinomab was able to stand out among so many excellent companies，fully demonstrating its outstanding strength in clinical trial level， and it is also a high recognition of the R&D level and influence of Chinese biopharmaceutical  companies in the international market.
 
Life Sciences Review published a commentary article titled “Zhuhai Trinomab Pharmaceutical Co., Ltd A New Paradigm in Tetanus Prevention” through an interview with  Wanmei Wang, MD, PhD, chief medical officer and senior vice president of Trinomab.

The layout of Life Sciences Review magazine
( Image source : Life Sciences Review )

The following is an excerpt from the magazine's review article:

Tetanus, a potentially fatal disease caused by the bacterium clostridium tetani, has long been a global health concern. Even with treatment, the mortality rate for tetanus can range from 30 to 50 percent, and if left untreated, it can escalate to 100 percent.

Traditional methods for preventing tetanus rely on the vaccination shots given in childhood and adolescence. However, plasma-derived products obtained from human blood donations, containing high-titer anti-tetanus antibodies, must be administered to individuals who have not been vaccinated, have uncertain vaccinationstatus, or have declined immunity. This is especially crucial when they sustain injuries, and the wounds are contaminated.
 
Plasma-derived products pose significant concerns, which include the risk of transmitting unknown diseases despite rigorous testing and the inconsistency in supply of plasma-derived products, leading to worldwide shortages.
 
In response to these challenges, Zhuhai Trinomab Pharmaceutical, a forward-thinking clinical-stage biopharmaceutical company, has introduced a first-in-class solution-TNM002 injection. It is a monoclonal antibody developed through the company's proprietary HitmAb® technology platform, which has emerged as a pioneer in discovering fully native human monoclonal antibodies (mAbs) to combat infectious diseases and other health conditions.
 
The HitmAb® platform boasts differentiated advantages, particularly exceptional efficiency in discovering fully native human mAbs.These mAbs closely resemble those naturally produced by the human body, making them highly effective and safe.
 
Some countries, including China, use animal-derived anti-sera from horses. In the case of China, they utilize a product known as equine Anti-Tetanus-Toxin, considered potentially hazardous. Developed countries ceased using them in the 1960s, and the World Health Organization (WHO) removed them from the essential drug list decades ago.
 
Zhuhai Trinomab Pharmaceutical is doing just that; it completed the entire clinical development program within an astonishing three-year timeframe. Its journey has been nothing short of remarkable.
 
“This accomplishment shines as an example of the successful synergy between strategic planning, innovative clinical trial design, and effective execution,” says Wanmei Wang, MD, PhD, chief medical officer and senior vice president of Zhuhai Trinomab Pharmaceutical.
 
The accelerated progress of TNM002 has led to the “Breakthrough” designation from the China NMPA and the US FDA “Fast-track" designation, respectively which underscores the impressive pace of innovation within the biopharmaceutical industry, with TNM002 set torevolutionize tetanus treatment.
 
Trinomab provides a compelling example of how cutting-edge technology and dedicated teamwork can bring about transformative change in healthcare. As TNM002 progresses, it has the potential to provide safer and more effective treatment options for those at risk of tetanus, saving lives and improving the quality of healthcare globally.